Sinecatechins
drugOn this page
Also known as Camellia sinensis catechinsCamellia sinensis leaf catechinsKunecatechinsPolyphenon eVeregen
Summary
Sinecatechins (CHEMBL1201723) is an approved unknown (ATC D06BB12); indicated across 4 conditions including viral infectious disease and basal cell carcinoma.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Unknown
- ATC class: D06BB12
- Indications: 4 conditions
- Clinical trials: 17
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1201723 |
| Name | Sinecatechins |
| Type | Unknown |
| Max phase | 4 |
| ATC | D06BB12 |
Also known as: Camellia sinensis catechins, Camellia sinensis leaf catechins, Kunecatechins, Polyphenon e, Sinecatechins, Veregen, SINECATECHINS
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
4 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| viral infectious disease | 4 | MONDO:0005108 | EFO:0000763 |
| basal cell carcinoma | 2 | MONDO:0020804 | EFO:0004193 |
| prostate carcinoma | 2 | MONDO:0005159 | EFO:0001663 |
| anogenital human papillomavirus infection | 1 | MONDO:0005647 | EFO:0007147 |
Clinical trials
Total trials: 17.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 8 |
| PHASE1 | 4 |
| PHASE4 | 1 |
| PHASE2/PHASE3 | 1 |
| PHASE3 | 1 |
| PHASE1/PHASE2 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02622568 | PHASE4 | COMPLETED | Investigating Veregen ™ 15% Ointment Treatment For Non-facial Verrucae in Pediatric Patients: A Pilot Study |
| NCT02029352 | PHASE2/PHASE3 | COMPLETED | Topical Green Tea Ointment in Treatment of Superficial Skin Cancer |
| NCT04055142 | PHASE3 | COMPLETED | Clinical Trial for Evaluating the Efficacy and Safety of Electrocoagulation vs Topic Sinecatechins vs Topic Cidofovir Within the Treatment to High-grade Anal Intraepithelial Neoplasia in HIV Homosexual Males |
| NCT04597359 | PHASE2 | ACTIVE_NOT_RECRUITING | To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring |
| NCT00005097 | PHASE2 | TERMINATED | Green Tea Extract in Treating Patients With Actinic Keratosis |
| NCT00088946 | PHASE2 | COMPLETED | Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder Cancer |
| NCT00262743 | PHASE1/PHASE2 | COMPLETED | Green Tea Extract in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia |
| NCT00363805 | PHASE2 | COMPLETED | Green Tea or Polyphenon E in Preventing Lung Cancer in Former Smokers With Chronic Obstructive Pulmonary Disease |
| NCT00596011 | PHASE2 | COMPLETED | Study of Polyphenon E in Men With High-grade Prostatic Intraepithelial Neoplasia |
| NCT00676793 | PHASE2 | COMPLETED | A Study of the Effect of Polyphenon E (Green Tea Extract) on Breast Cancer Progression |
| NCT01060345 | PHASE2 | TERMINATED | A Pilot Study of Chemo-prevention of Green Tea in Women With Ductal Carcinoma in Situ |
| NCT01451723 | PHASE2 | TERMINATED | Safety and Neuroprotective Effects of Polyphenon E in MS; Phase II |
| NCT00707252 | PHASE1 | TERMINATED | Study of Polyphenon E in Addition to Erlotinib in Advanced Non Small Cell Lung Cancer |
| NCT00836719 | PHASE1 | COMPLETED | Safety of Polyphenon E in Multiple Sclerosis Pilot Study |
| NCT01433289 | PHASE1 | COMPLETED | Study to Evaluate Safety and Toxicity of Polyphenon E (EGCG) in HIV-1-Infected Individuals |
| NCT01490008 | PHASE1 | COMPLETED | Systemic Exposure of Catechins From Veregen 15% Ointment in Patients With External Anogenital Warts and From Oral Intake of Green Tea Beverage in Healthy Volunteers |
| NCT02147353 | Not specified | COMPLETED | Treatment of External Genital Warts With Cryotherapy and Sinecatechins 15% Ointment |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: viral infectious disease